home / stock / moln / moln articles

MOLN Articles, Molecular Partners AG - From 06/11/24

Stock Information
Company Name: Molecular Partners AG
Stock Symbol: MOLN
Market: NASDAQ
Website: molecularpartners.com
Menu
MOLN MOLN Quote MOLN Short MOLN News MOLN Articles MOLN Message Board
Get MOLN Alerts

News, Short Squeeze, Breakout and More Instantly...
Molecular Partners and Orano Med Share Positive Preclinical Data of their DLL3-Targeting Radio-DARPin Therapy (RDT) Candidate MP0712 at SNMMI 2024 | Benzinga

MP0712, a 212Pb-Radio-DARPin targeting DLL3, as first candidate of Molecular Partners' RDT platform in development in partnership with Orano...
Why Science Applications International Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Monday's Mid-Day Session | Benzinga

Shares of Science Applications International Corporation (NASDAQ:SAIC) declined 11% to $119.91 following first-quarter results. SAIC reported a 9% ...

Why GameStop Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket | Benzinga

Shares of GameStop Corp. (NYSE:GME) rose sharply in today's pre-market trading . The rally in the stock came on the back of Keith Gill, also k...

Molecular Partners Announces Dismissal of Class Action Lawsuit | Benzinga

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 01, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinica...
Molecular Partners To Hold Conference Call to Discuss Fourth Quarter and Full Year 2023 Results and Announces Upcoming Investor Presentations | Benzinga

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 01, 2024 (GLOBE NEWSWIRE) -- Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinica...

Molecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare Conference | Benzinga

Tetra-specific T-cell engager MP0533 for patients with r/r AML and AML/MDS on track to deliver expanded clinical phase 1/2a data in H1 2024 Progr...

Molecular Partners to Present at 42nd Annual J.P. Morgan Healthcare Conference and Swiss Investor Conferences | Benzinga

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG ((SIX: MOLN, NASDAQ:MOLN), a clinical-...
Molecular Partners to Present on DARPin Oncology Innovations at Protein & Antibody Engineering Summit Europe (PEGS) | Benzinga

Presentation will highlight versatility of DARPin designs in enabling conditional activation of the immune system to fight tumors, addressing tox...

Molecular Partners Presents Updated Positive Data from Ongoing Phase 1 Trial of MP0317 (FAP X CD40) Monotherapy in Patients with Advanced Solid Tumors at the 2023 SITC Annual Meeting | Benzinga

MP0317 continues to demonstrate tumor-localized CD40 activation, leading to elevated immune activity in the tumor microenvironment MP0317 monot...

Molecular Partners to Present Initial Data from Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at the 65th ASH Annual Meeting and Exposition | Benzinga

MP0533 shows acceptable safety profile in first three dose cohorts (5 patients total, data cut-off July 20); reported adverse reactions are of Gr...
Previous 10 Next 10